Apollon Wealth Management, LLC Cassava Sciences Inc Transaction History

Apollon Wealth Management, LLC

$3.14 Billion
Q1 2024

A detailed history of Apollon Wealth Management, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Apollon Wealth Management, LLC holds 11,562 shares of SAVA stock, worth $136,315. This represents 0.01% of its overall portfolio holdings.

Number of Shares

11,562

Previous 10,672 8.34%

Holding current value

$136,315

Previous $240,000 2.5%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	BUY	$18.44 - $26.41 $16,411 - $23,504	890 Added 8.34%	11,562 $234,000
Q4 2023 Feb 06, 2024	BUY	$12.64 - $30.11 $897 - $2,137	71 Added 0.67%	10,672 $240,000
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $32,464 - $49,399	1,951 Added 22.55%	10,601 $176,000
Q2 2023 Aug 04, 2023	SELL	$21.59 - $27.88 $26,296 - $33,957	-1,218 Reduced 12.34%	8,650 $212,000
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $65,336 - $101,485	2,785 Added 39.32%	9,868 $238,000

Q4 2022 Feb 15, 2023	SELL	$27.82 - $44.16 $3,254 - $5,166	-117 Reduced 1.63%	7,083 $209,000
Q3 2022 Nov 08, 2022	SELL	$16.33 - $51.06 $31,418 - $98,239	-1,924 Reduced 21.09%	7,200 $301,000
Q2 2022 Aug 11, 2022	BUY	$17.22 - $38.47 $1,343 - $3,000	78 Added 0.86%	9,124 $257,000
Q1 2022 May 16, 2022	BUY	$32.6 - $53.05 $13,105 - $21,326	402 Added 4.65%	9,046 $336,000
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $10,111 - $25,000	275 Added 3.29%	8,644 $378,000
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $80,445 - $260,452	1,925 Added 29.87%	8,369 $520,000
Q2 2021 Aug 12, 2021	BUY	$32.15 - $89.72 $12,249 - $34,183	381 Added 6.28%	6,444 $551,000
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $42,986 - $533,240	6,063 New	6,063 $273,000

Others Institutions Holding SAVA

# of Institutions

172

Shares Held

11.3M

Call Options Held

1.61M

Put Options Held

1.43M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $473M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Apollon Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Apollon Wealth Management, LLC with notifications on news.

Account

Apollon Wealth Management, LLC Cassava Sciences Inc Transaction History